Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction

American Heart Journal

Volumn 141, Issue 3, 2001, Pages 367-374

  Maisel, Alan S ^a   Koon, Jen ^a   Krishnaswamy, Padma ^a   Kazenegra, Radmila ^a   Clopton, Paul ^a   Gardetto, Nancy ^a   Morrisey, Robin ^a   Garcia, Alex ^a   Chiu, Albert ^a   De Maria, Anthony ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIASTOLE; FEMALE; HEART LEFT VENTRICLE FAILURE; HUMAN; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCREENING TEST; SYSTOLE;

EID: 0035091745     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2001.113215     Document Type: Article

References (48)

1. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction
2. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement trial: The SAVE Investigators
3. The limited availability of physical signs for estimating hemodynamics in chronic heart failure
4. Validity of clinical diagnosis of heart failure in primary health care
5. Prospects for using a blood sample in the diagnosis of heart failure
6. Recommendations concerning use of echocardiography in hypertension and general population research
7. Efficient utilization of echocardiography for the assessment of left ventricular systolic function
8. Rapid transcriptional activation and early mRNA turnover of BNP in cardiocyte hypertrophy: Evidence for BNP as an "emergency" cardiac hormone against ventricular overload
9. Different secretion pattern of atrial natriuretic peptide and brain natriuretic peptide in patients with CHF
10. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction
11. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure
12. Brain natriuretic peptide predicts mortality in the elderly
13. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care
14. Biochemical detection of left-ventricular systolic dysfunction
15. Plasma brain natriuretic peptide in assessment of acute dyspnea
16. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction
17. Superiority of brain natriuretic peptide is related to diastolic dysfunction in hypertension
18. A rapid bedside test for brain natriuretic peptide accurately predicts cardiac function in patients referred for echocardiography
19. Diastolic dysfunction and natriuretic peptides in systolic heart failure
20. Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: Implications for clinical practice
21. An experimental study of cardiac natriuretic peptides as markers of development of CHF
22. CHF: Involvement of perivascular peptides reflecting activity in sympathetic, parasympathetic and afferent fibers
23. Left ventricular volume from paired biplane two-dimensional echocardiography
24. Clinical utility of transthoracic two-dimensional and Doppler echocardiography
25. Cross-sectional study of contribution of clinical assessment and simple cardiac investigations to diagnosis of left ventricular systolic dysfunction in patients admitted with acute dyspnea
26. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
27. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)
28. Activation of neurohumoral systems in post infarction left ventricular dysfunction
29. Neuroendocrine activity in untreated heart failure
30. Hormones regulating cardiovascular functioning patients with severe congestive heart failure and their relation to mortality
31. Prognostic value of plasma intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure
32. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
33. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
34. An experimental study of cardiac natriuretic peptides as markers of development of CHF
35. CHF: Involvement of perivascular peptides reflecting activity in sympathetic, parasympathetic and afferent fibers
36. Natriuretic peptides-relevance in cardiac disease
37. Predictive properties of serum prostate-specific antigen testing in a community-based setting
38. Enhancing and evaluating diagnostic accuracy
39. Meta-analysis of Pap test accuracy
40. How to diagnose diastolic heart failure
41. Isolated diastolic dysfunction in the community
42. Usefulness of a rapid, bedside test for brain natriuretic peptide in the evaluation of patients presenting to the emergency room with possible congestive heart failure
43. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population
44. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions and congestive heart failure
45. Natriuretic peptides in assessment of left-ventricular dysfunction
46. Treatment of heart failure guided by plasma amino terminal brain natriuretic peptide (N-BNP) concentrations
47. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: Randomized comparisan of hemodynamic and neuroendocrine effects of tailored versus empirical therapy